Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREAT-HAP
2023-503480-42-00Phase 3Withdrawn
- Sponsor
- CHU de Nantes
- Start
- Jul 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 3, randomised trial in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) comparing Baricitinib + standard of care with Standard of care (2 arms). Planned start Jul 2023; status: withdrawn.
02
Drugs
baricitinib
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on 2023-503480-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503480-42-00.